<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639011</url>
  </required_header>
  <id_info>
    <org_study_id>H-40569</org_study_id>
    <nct_id>NCT04639011</nct_id>
  </id_info>
  <brief_title>Duloxetine Tibial Plateau</brief_title>
  <official_title>Effects of Duloxetine on Postoperative Pain Control and Knee Rehabilitation After Open Reduction Internal Fixation of Tibial Plateau Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Duloxetine provides effective pain management&#xD;
      for adult patients (18 or older) undergoing tibial plateau surgery. Participants from two&#xD;
      institutions will be randomized to one of two treatment groups: control (Group A) and&#xD;
      treatment (Group B). Group A control group will receive placebo of sugar pill and BMC&#xD;
      standard of care - namely postoperative, IV administration of opioids via a patient&#xD;
      controlled analgesia (PCA) system which utilizes a hydromorphone pump (BMC standard of care).&#xD;
      Group B, the intervention group, will receive three doses of 60 mg of oral duloxetine (right&#xD;
      before operation, postop day 1, postop day 2).&#xD;
&#xD;
      This study is important as tibial plateau surgery's postoperative pain management primarily&#xD;
      involved providing opioids, and if duloxetine can result in reduced narcotic intake and lower&#xD;
      pain scores, it can potentially improve patient care, rehabilitation, early movement, and&#xD;
      shorter length of hospital stay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain levels in the first 16 hours after surgery</measure>
    <time_frame>every 4 hours up to 16 hours</time_frame>
    <description>A visual analog pain scale (VAS) will be used to assess postoperative pain levels. Participants will make a mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; HIgher scores reflect greater pain levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain level 24 hours after surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>A visual analog pain scale (VAS) will be used to assess the postoperative pain level. Participants will make a mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; HIgher scores reflect greater pain levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain level 36 hours after surgery</measure>
    <time_frame>36 hours</time_frame>
    <description>A visual analog pain scale (VAS) will be used to assess the postoperative pain level. Participants will make a mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot; HIgher scores reflect greater pain levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>up to 10 days post op</time_frame>
    <description>The total morphine consumption will be calculated using the Centers for Disease Control (CDC) morphine equivalents [ME].Determine the total daily amount of morphine taken; convert to MEs by multiplying the daily dosage for each opioid by its conversion factor [which is =1 for morphine]; then add all morphine MEs together.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in knee range of motion</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
    <description>The knee range of motion will be abstracted from the electronic medical record. Knee range of motion ranges from 0 to 140 degrees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported functional status at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Functional status will be assessed using the Short Musculoskeletal Function Assessment (SMFA). SMFA is a 46 item questionnaire. It consists of the dysfunction index, which has 34 items for the assessment of patient function, and the bother index, which has 12 items for the assessment of how much patients are bothered by functional problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self reported functional status at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Functional status will be assessed using the Short Musculoskeletal Function Assessment (SMFA). SMFA is a 46 item questionnaire. It consists of the dysfunction index, which has 34 items for the assessment of patient function, and the bother index, which has 12 items for the assessment of how much patients are bothered by functional problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>12 weeks</time_frame>
    <description>The hospital length of stay will be measured in days, calculated by subtracting the date of admission from the date of discharge as recorded in the electronic medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mobilization (starting to walk)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time to mobilization will be calculated by subtracting the date the participant started to walk post operatively from the date of surgery as recorded in the electronic medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulation (walking) distance on post-op days 1 or 2</measure>
    <time_frame>Up to 2 days post op</time_frame>
    <description>The walking distance will be abstracted from the electronic medical record.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Tibial Plateau Fracture</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group A Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to Group A will receive placebo (sugar pill) and Boston Medical Center (BMC) standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Groups B Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to Group B will receive duloxetine and Boston Medical Center (BMC) standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)</description>
    <arm_group_label>Groups B Intervention</arm_group_label>
    <other_name>Serotonin-norepinephrine reuptake inhibitor (SNRI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).</description>
    <arm_group_label>Group A Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (SOC) for tibial plateau surgery</intervention_name>
    <description>Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.</description>
    <arm_group_label>Group A Placebo</arm_group_label>
    <arm_group_label>Groups B Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tibial plateau fracture that requires operative fixation&#xD;
&#xD;
          -  Ambulatory patient prior to fracture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous tibial plateau fracture on ipsilateral knee&#xD;
&#xD;
          -  History of Complex Regional Pain Syndrome in ipsilateral extremity&#xD;
&#xD;
          -  History of any demyelinating disorder or neurologic deficit that may contribute to&#xD;
             altered pain tolerance/sensation&#xD;
&#xD;
          -  Acute or chronic knee infection in ipsilateral extremity&#xD;
&#xD;
          -  Previous total knee arthroplasty or knee hemiarthroplasty in ipsilateral knee&#xD;
&#xD;
          -  Allergy to morphine (used in the SOC PCA pump)&#xD;
&#xD;
          -  Pregnant or breastfeeding as determined by standard of care pre-operative urine&#xD;
             pregnancy test&#xD;
&#xD;
          -  Polytrauma&#xD;
&#xD;
          -  Open fracture&#xD;
&#xD;
          -  IV drug user&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Revision cases&#xD;
&#xD;
          -  Non-ambulatory&#xD;
&#xD;
          -  Anatomical deformities of the knee&#xD;
&#xD;
          -  Hepatic dysfunction or cirrhosis&#xD;
&#xD;
          -  Taking Selective Serotonin Reuptake Inhibitor (SSRI), serotonin-norepinephrine&#xD;
             reuptake Inhibitor (SNRI), monoamine oxidase inhibitors (MAOIs), tri- or tetra- cyclic&#xD;
             anti-depressant&#xD;
&#xD;
          -  Renal impairment (mention in patient chart and/or creatinine clearance &lt;30)&#xD;
&#xD;
          -  Moderate to severe depression&#xD;
&#xD;
          -  Taking CYP1A2 inhibitors and CYP1A6 inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seroos Salavati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seroos Salavati, MD</last_name>
    <phone>914-525-76067</phone>
    <email>seroos.salavati@bmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aneesh Samineni, BA</last_name>
    <email>samineni@bu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Seroos Salavati, MD</last_name>
      <email>seroos.salavati@bmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duloxetine</keyword>
  <keyword>VAS pain scores</keyword>
  <keyword>Patient Controlled Analgesia (PCA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

